GSK vs Merck &: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

GSK plc (GSK.LSE)

Q3 202630 Jun – 9 Oct 2026

▲2▼1

GSK's pipeline wins and cost cuts offset drug setbacks

FDA approves first lung cancer drug Jiditro GSK won FDA approval for Jiditro, its first lung cancer medicine. This opens a new treatment area and shows the pipeline can deliver, giving investors a fresh growth driver.
New approval is a major pipeline win that supports future revenue.
Strong Q2 results and raised guidance GSK reported strong second-quarter results and raised its full-year guidance. Specialty Medicines grew 14%, and the company announced £1.9bn in cost savings plus share buybacks, boosting confidence.
Financial performance and capital returns directly lift investor sentiment.
Camlipixant dropped and legal/patent risks GSK scrapped chronic cough drug camlipixant, a potential £2.5bn product, and faces an AnaptysBio lawsuit over Jemperli rights. An HIV patent cliff for dolutegravir looms around 2028–29, adding uncertainty.
These setbacks remove a major revenue hope and raise legal and patent concerns.
Vaccine restructuring and mRNA competition GSK is cutting 641 jobs in Dresden as part of vaccine restructuring, while facing rising mRNA flu competition from Moderna. Cost discipline helps, but competitive pressure and job cuts signal challenges.
Restructuring shows cost focus but also competitive and operational pressures.

August 202624 Jul – 9 Oct 2026

▲3

GSK gains on cost cuts, pipeline wins, and raised guidance

Cost savings and UK investment GSK announced a £1.9bn cost-savings plan to fund late-stage trials, a £400m UK investment, and a new Cambridge R&D hub. These moves aim to boost efficiency and innovation, supporting future growth.
This is a major new financial and strategic initiative that lifted shares.
Strong Q2 results and raised guidance Q2 profit beat expectations, sales rose 5% to over £8.4bn, and full-year guidance was raised. However, EPS guidance fell due to Nuvalent interest costs, a mixed detail for investors.
Earnings performance and guidance are key drivers of stock price.
Pipeline and regulatory wins GSK won priority review for Jemperli in rectal cancer, Japan's first approval of hepatitis B cure Hibsago, and Phase III progress for its mRNA flu vaccine. These advances strengthen its oncology and vaccine portfolios.
Pipeline successes directly support future revenue growth and investor confidence.
Strategic expansion and competitive risks GSK raised its long-term sales target above £40bn, added Wave Life Sciences' RNA candidate, and expanded US manufacturing. But Moderna's approved mRNA flu vaccine challenges GSK's flu franchise, and Europe's drug industry is losing ground.
This captures both growth initiatives and emerging competitive threats.

Latest24 Jul – 9 Oct 2026

▲3

GSK lifts long-term sales target, buys pipeline assets, expands US manufacturing

GSK raises sales target above consensus, oncology leads GSK now targets over £40 billion in sales, above the £36.4 billion analysts expected, with oncology drugs the main upside. A £1.9 billion cost-saving plan funds pipeline investment and cushions upcoming patent losses. Higher expected sales and stable margins support the share price.
This is the period's biggest company-specific news and directly lifts the long-term earnings outlook.
Pipeline and manufacturing expansion in the US GSK added Wave Life Sciences' liver-disease RNA candidate, expanded tuberculosis research with Gates Foundation funding, and will invest over $800 million in Pennsylvania, adding about 300 jobs and new biologics plants. More pipeline and US capacity support future growth.
Shows concrete new investment in pipeline and manufacturing that underpins future revenue.
US measles outbreak lifts MMR vaccine demand US measles cases hit a 35-year high, with 3,471 cases and deaths acknowledged by the CDC, and 95% of cases in unvaccinated people. GSK markets the MMR vaccine, so rising vaccination demand supports its vaccines business.
A real demand driver for an existing GSK product, though smaller than the core strategy news.
Europe warns on drug industry; US 340B pilot includes GSK GSK joined rivals warning Europe's drug industry is losing ground, with slow patient access and weak incentives weighing on the sector. Separately, GSK was picked for a US 340B rebate pilot from January, a modest regulatory positive.
Captures the main regulatory backdrop, both the European headwind and a small US positive.

September 202610 Sep – 18 Sep 2026

▲2▼1

GSK pipeline wins and buybacks offset HIV patent cliff and flu competition

Specialty Medicines growth and pipeline expansion GSK's Specialty Medicines sales rose 14% in H1 2026, now over 40% of total sales, with double-digit growth in HIV, respiratory, immunology and oncology. The company plans more than 20 late-stage studies in 2026, more than double its original target, supporting long-term revenue growth and lifting the shares.
This shows the core growth engine that is driving GSK's earnings and share price higher.
HIV patent cliff looms GSK faces loss of exclusivity for dolutegravir, the backbone of its HIV medicines, with patents expiring in major markets around 2028-2029. Those products generated £2.74 billion in H1 2026 sales, so the eventual loss of protection threatens a significant revenue stream and weighs on the share price.
This is a major medium-term risk that could pressure future earnings and investor sentiment.
Oncology pipeline boosted by lung cancer data and Chimagen deal GSK rose 4.7% after positive trial results for two lung cancer treatments. It also acquired full global rights to Chimagen's trispecific T-cell engager for multiple myeloma for up to $750 million, expanding its oncology pipeline and reinforcing growth prospects.
These are concrete pipeline advances that directly lifted the stock and add new oncology assets.
Vaccine restructuring and mRNA flu advance GSK will close its Dresden vaccine plant by 2027, cutting 641 jobs, to consolidate flu vaccine production in Canada amid falling demand for egg-based vaccines. At the same time, it advanced its mRNA flu vaccine to Phase III after strong mid-stage results, aiming to defend its flu franchise against new competitors like Moderna.
This shows GSK cutting costs and investing in next-generation vaccines to offset competitive threats.

10 Sep – 18 Sep 2026

▲2▼1

GSK pipeline wins and buybacks offset HIV patent cliff and flu competition

Specialty Medicines growth and pipeline expansion GSK's Specialty Medicines sales rose 14% in H1 2026, now over 40% of total sales, with double-digit growth in HIV, respiratory, immunology and oncology. The company plans more than 20 late-stage studies in 2026, more than double its original target, supporting long-term revenue growth and lifting the shares.
This shows the core growth engine that is driving GSK's earnings and share price higher.
HIV patent cliff looms GSK faces loss of exclusivity for dolutegravir, the backbone of its HIV medicines, with patents expiring in major markets around 2028-2029. Those products generated £2.74 billion in H1 2026 sales, so the eventual loss of protection threatens a significant revenue stream and weighs on the share price.
This is a major medium-term risk that could pressure future earnings and investor sentiment.
Oncology pipeline boosted by lung cancer data and Chimagen deal GSK rose 4.7% after positive trial results for two lung cancer treatments. It also acquired full global rights to Chimagen's trispecific T-cell engager for multiple myeloma for up to $750 million, expanding its oncology pipeline and reinforcing growth prospects.
These are concrete pipeline advances that directly lifted the stock and add new oncology assets.
Vaccine restructuring and mRNA flu advance GSK will close its Dresden vaccine plant by 2027, cutting 641 jobs, to consolidate flu vaccine production in Canada amid falling demand for egg-based vaccines. At the same time, it advanced its mRNA flu vaccine to Phase III after strong mid-stage results, aiming to defend its flu franchise against new competitors like Moderna.
This shows GSK cutting costs and investing in next-generation vaccines to offset competitive threats.

13 Aug – 3 Sep 2026

▲2▼1

GSK pipeline wins and cost cuts drive gains, Moderna flu threat weighs

Jemperli priority review for rectal cancer The FDA accepted GSK's Jemperli for priority review in locally advanced rectal cancer, with a decision expected by February 2027. Positive trial data showed patients had no detectable cancer for at least a year. This raises hopes for a new revenue stream and lifts the shares.
A new regulatory milestone for a key cancer drug adds to GSK's growth outlook.
Moderna's mRNA flu vaccine approval Moderna won FDA approval for the first mRNA flu vaccine, for adults 50 and over, directly challenging GSK's flu vaccine business. While uptake depends on pricing and pharmacy stocking, it introduces a new competitor in a market GSK has long led, which could pressure future sales and the share price.
This is a competitive threat to GSK's established flu vaccine franchise.
Hepatitis B cure and mRNA flu advance GSK won the world's first approval for Hibsago, a functional cure for chronic hepatitis B, in Japan. It also advanced its own mRNA flu vaccine to Phase III after positive mid-stage data. Both are new pipeline wins that could drive long-term growth and support the shares.
Two separate pipeline successes show GSK's research is delivering new products.

27 Jul – 6 Aug 2026

▲4

GSK's cost cuts and pipeline push lift shares despite profit dip

£1.9bn savings drive and UK investment GSK launched a three-year £1.9bn cost-savings plan to fund late-stage drug trials and simplify the business, plus a £400m UK investment including a new R&D centre. Shares jumped 4.2% as investors welcomed the plan to protect profits while spending on new drugs.
This is the main new event that directly moved the share price up and shows management's plan to fund growth.
Q2 profit beat and raised sales guidance GSK beat second-quarter profit expectations, with sales up 5% to over £8.4bn and core earnings per share up 9%. It raised full-year sales and operating profit guidance to the upper half of its range, though it lowered EPS guidance due to extra interest costs from the Nuvalent deal.
The earnings beat and guidance raise are new and directly support the share price, while the EPS cut is a real counterweight.
AI drug discovery partnership and Cambridge R&D hub GSK expanded its AI drug discovery collaboration with Relation Therapeutics, worth up to $110m, and announced a new Cambridge R&D hub for over 1,000 scientists. These moves aim to speed up finding new drugs and strengthen GSK's long-term pipeline.
This is a new strategic step that could improve future growth prospects, though the financial impact is longer-term.
Record UK lab space demand from GSK prelet GSK's 300,000-square-foot prelet at Cambridge Biomedical Campus helped push UK lab space demand to a record high. This shows GSK is investing in research capacity, but high lab vacancies and slowing construction are a broader industry caution.
It confirms GSK's commitment to UK R&D and signals demand for its facilities, a new positive signal for the company's growth plans.

July 202630 Jun – 24 Jul 2026

▲2▼2

GSK's lung cancer win offset by pipeline setback and legal risk

FDA approves first lung cancer drug Jiditro GSK won early FDA approval for Jiditro, its first lung cancer drug, for previously treated ROS1-positive NSCLC. This opens a new high-margin oncology market and supports GSK's goal of over £40bn revenue by 2031, lifting investor confidence.
This is a major new approval that directly boosts GSK's oncology growth story and revenue outlook.
GSK drops chronic cough drug camlipixant GSK stopped developing camlipixant after mixed late-stage trial results, removing a potential £2.5bn-a-year product. Shares fell up to 4.5%. Analysts called it a credibility hit and questioned GSK's acquisition strategy, adding pressure on management.
This is a fresh pipeline failure that removes a key late-stage asset and hurts sentiment.
AnaptysBio lawsuit over Jemperli rights AnaptysBio accuses GSK of violating their commercial agreement for Jemperli. A trial began July 14-17. If AnaptysBio wins, GSK could lose rights to the drug. Even a settlement or acquisition could cost GSK, creating uncertainty.
This legal risk could threaten a marketed cancer drug and is a new overhang on the stock.
Pipeline progress: Ris-Rez and Bexsero Hansoh's Ris-Rez showed survival benefit in lung cancer; GSK holds ex-China rights. EMA accepted a Bexsero label update for a single-dose booster in adolescents. Both support future sales growth and strengthen GSK's vaccine and oncology portfolios.
These are new positive clinical and regulatory milestones that add to GSK's growth pipeline.

30 Jun – 24 Jul 2026

▲2▼2

GSK's lung cancer win offset by pipeline setback and legal risk

FDA approves first lung cancer drug Jiditro GSK won early FDA approval for Jiditro, its first lung cancer drug, for previously treated ROS1-positive NSCLC. This opens a new high-margin oncology market and supports GSK's goal of over £40bn revenue by 2031, lifting investor confidence.
This is a major new approval that directly boosts GSK's oncology growth story and revenue outlook.
GSK drops chronic cough drug camlipixant GSK stopped developing camlipixant after mixed late-stage trial results, removing a potential £2.5bn-a-year product. Shares fell up to 4.5%. Analysts called it a credibility hit and questioned GSK's acquisition strategy, adding pressure on management.
This is a fresh pipeline failure that removes a key late-stage asset and hurts sentiment.
AnaptysBio lawsuit over Jemperli rights AnaptysBio accuses GSK of violating their commercial agreement for Jemperli. A trial began July 14-17. If AnaptysBio wins, GSK could lose rights to the drug. Even a settlement or acquisition could cost GSK, creating uncertainty.
This legal risk could threaten a marketed cancer drug and is a new overhang on the stock.
Pipeline progress: Ris-Rez and Bexsero Hansoh's Ris-Rez showed survival benefit in lung cancer; GSK holds ex-China rights. EMA accepted a Bexsero label update for a single-dose booster in adolescents. Both support future sales growth and strengthen GSK's vaccine and oncology portfolios.
These are new positive clinical and regulatory milestones that add to GSK's growth pipeline.

Q2 202617 Jun – 24 Jun 2026

▲3▼1

GSK's pipeline and dealmaking drive gains, but tariff risk lingers

FDA approval of Utebzi GSK and Spero won FDA approval for Utebzi, the first oral carbapenem for complicated UTIs. This opens a new market and strengthens GSK's anti-infectives portfolio, with launch expected by end-2026.
This is a concrete regulatory win that directly boosts GSK's revenue prospects.
M&A surge and GSK's Nuvalent deal Biopharma M&A hit a six-year high with $65 billion in Q1 deals, and GSK is acquiring Nuvalent for $10.6 billion. This shows GSK is actively filling pipeline gaps, which investors view as a growth signal.
The Nuvalent acquisition is a major strategic move that addresses pipeline concerns and reflects industry confidence.
Physician interest in Benlysta for CTD-ILD A survey shows rheumatologists are highly interested in GSK's Benlysta for CTD-ILD, a condition with few effective treatments. This hints at potential expanded use and future sales growth.
It points to a possible new indication for an existing GSK drug, which could add revenue.
US tariff and policy concerns Industry confidence is high, but 69% of executives cite US tariffs and government actions as the biggest worry, rising to 78% among Europeans. For GSK, a UK-based company, this could mean higher costs or barriers in its largest market.
It provides a real counterweight to the positive news, highlighting a risk that could pressure the stock.

June 202617 Jun – 24 Jun 2026

▲3▼1

GSK's pipeline and dealmaking drive gains, but tariff risk lingers

FDA approval of Utebzi GSK and Spero won FDA approval for Utebzi, the first oral carbapenem for complicated UTIs. This opens a new market and strengthens GSK's anti-infectives portfolio, with launch expected by end-2026.
This is a concrete regulatory win that directly boosts GSK's revenue prospects.
M&A surge and GSK's Nuvalent deal Biopharma M&A hit a six-year high with $65 billion in Q1 deals, and GSK is acquiring Nuvalent for $10.6 billion. This shows GSK is actively filling pipeline gaps, which investors view as a growth signal.
The Nuvalent acquisition is a major strategic move that addresses pipeline concerns and reflects industry confidence.
Physician interest in Benlysta for CTD-ILD A survey shows rheumatologists are highly interested in GSK's Benlysta for CTD-ILD, a condition with few effective treatments. This hints at potential expanded use and future sales growth.
It points to a possible new indication for an existing GSK drug, which could add revenue.
US tariff and policy concerns Industry confidence is high, but 69% of executives cite US tariffs and government actions as the biggest worry, rising to 78% among Europeans. For GSK, a UK-based company, this could mean higher costs or barriers in its largest market.
It provides a real counterweight to the positive news, highlighting a risk that could pressure the stock.

17 Jun – 24 Jun 2026

▲3▼1

GSK's pipeline and dealmaking drive gains, but tariff risk lingers

FDA approval of Utebzi GSK and Spero won FDA approval for Utebzi, the first oral carbapenem for complicated UTIs. This opens a new market and strengthens GSK's anti-infectives portfolio, with launch expected by end-2026.
This is a concrete regulatory win that directly boosts GSK's revenue prospects.
M&A surge and GSK's Nuvalent deal Biopharma M&A hit a six-year high with $65 billion in Q1 deals, and GSK is acquiring Nuvalent for $10.6 billion. This shows GSK is actively filling pipeline gaps, which investors view as a growth signal.
The Nuvalent acquisition is a major strategic move that addresses pipeline concerns and reflects industry confidence.
Physician interest in Benlysta for CTD-ILD A survey shows rheumatologists are highly interested in GSK's Benlysta for CTD-ILD, a condition with few effective treatments. This hints at potential expanded use and future sales growth.
It points to a possible new indication for an existing GSK drug, which could add revenue.
US tariff and policy concerns Industry confidence is high, but 69% of executives cite US tariffs and government actions as the biggest worry, rising to 78% among Europeans. For GSK, a UK-based company, this could mean higher costs or barriers in its largest market.
It provides a real counterweight to the positive news, highlighting a risk that could pressure the stock.

Merck & Company Inc (MRK)

Latest27 Sep – 8 Oct 2026

▲3▼1

Merck's pipeline wins offset Keytruda patent setback

Tulisokibart succeeds in hidradenitis suppurativa Merck's anti-TL1A antibody tulisokibart met its main goal in a mid-stage trial for hidradenitis suppurativa, with 72% of high-dose patients responding versus 35% on placebo. This is the first positive Phase 2 data for this drug class in dermatology, opening a new growth area beyond cancer.
New clinical win shows pipeline diversification, supporting future revenue and stock price.
KRAS inhibitor licensed for up to $2.13 billion Merck paid $400 million upfront to license SciBrunch's SPR2015, a KRAS G12D inhibitor for pancreatic, colorectal and lung cancers. The deal adds a promising early-stage oncology asset, though the upfront charge will slightly reduce near-term reported earnings.
New licensing deal expands oncology pipeline, a key part of Merck's strategy to replace Keytruda revenue.
Dutch court blocks subcutaneous Keytruda in Europe A Dutch court banned Merck from making and selling subcutaneous Keytruda in eight European countries after Halozyme's patent win. The IV form is unaffected, but this blocks a key reformulation ahead of patent expiry, pressuring the stock.
New legal setback directly threatens a major Keytruda growth strategy in Europe.
WELIREG plus LENVIMA approved for kidney cancer The FDA approved Merck's WELIREG combined with LENVIMA for advanced kidney cancer after prior immunotherapy. This expands Merck's oncology portfolio beyond Keytruda, adding a new revenue stream and strengthening its cancer franchise.
New FDA approval diversifies oncology revenue, supporting long-term growth.

Q3 202630 Jun – 30 Sep 2026

▲3

Merck's Q3: Pipeline Wins and Guidance Raise Offset Keytruda Threats

Keytruda Label Expansions and Phase 3 Wins Merck expanded Keytruda's labels in breast and bladder cancer and reported a Phase 3 win in endometrial cancer. These broaden use and support sales growth, helping offset looming competition.
Shows continued growth for Merck's top drug, a key positive for the quarter.
FDA Approves LIPFENDRA, First Oral PCSK9 Inhibitor Merck won FDA approval for LIPFENDRA, the first oral PCSK9 inhibitor for high cholesterol. This opens a new market and diversifies revenue beyond oncology.
A major new product approval that adds a new growth driver.
Q2 Beat and Raised Full-Year Guidance Merck beat Q2 estimates with $16.61 billion revenue and raised full-year guidance to $66.3–67.3 billion. The strong results and outlook boosted investor confidence.
Directly reflects financial performance and management confidence.
Keytruda Competitive Threats and Other Headwinds Keytruda faces threats from ivonescimab, AstraZeneca's $2 billion Summit investment, and a pre-2028 biosimilar. Also, a congressional probe, generic Janumet XR, lost COVID revenue, and acquisition charges weighed.
Highlights the main risks that could pressure Merck's stock despite positives.

September 202630 Aug – 30 Sep 2026

▲2▼1

Merck's mRNA vaccine and new cholesterol drug shine, but Keytruda threats loom

FDA approves LIPFENDRA, first oral PCSK9 cholesterol drug The FDA approved LIPFENDRA, the first oral PCSK9 cholesterol drug, offering a new growth driver in a large market and potentially boosting Merck's revenue outlook.
This is a new product approval that expands Merck's commercial portfolio.
Pipeline expansions and label wins Merck advanced its pipeline with tulisokibart, a KRAS licensing deal, and oral delivery technology, while gaining label expansions for Keytruda, Winrevair, and Welireg, offsetting patent-cliff worries.
These moves strengthen Merck's long-term growth prospects and diversify its revenue base.
Keytruda faces competitive threats Keytruda faces mounting threats: Summit's ivonescimab beat it in lung cancer survival, AstraZeneca invested $2 billion in Summit, and a pembrolizumab biosimilar is coming before the 2028 patent expiry.
Keytruda is Merck's top-selling drug, so competition could significantly hurt future revenue.

20 Sep – 25 Sep 2026

▲3▼1

Merck's Label Wins and Pipeline Progress Offset Keytruda Competition

Multiple FDA and global label expansions for Keytruda, Winrevair, and Welireg Merck won FDA label updates for Winrevair (adding Phase 3 HYPERION data showing 76% reduction in clinical worsening) and Welireg plus Lenvima for advanced kidney cancer, plus Japanese approval for subcutaneous Keytruda across all indications. These expand approved uses and strengthen revenue durability.
These regulatory wins directly broaden Merck's product labels and market reach, supporting future sales growth.
Pipeline advances in remigromig and Keytruda combinations Merck's remigromig met its primary goal in a Phase IIb/III diabetic macular edema study, a first-in-class eye drug. Also, Inhibrx's INBRX-106 combined with Keytruda nearly doubled response rates in head and neck cancer, reinforcing Keytruda's backbone role.
These pipeline successes show Merck's R&D engine is producing new growth drivers beyond current drugs.
Keytruda faces competitive and regulatory setbacks Summit's ivonescimab cut death risk 27% versus Keytruda in lung cancer, a direct threat. Separately, Merck and Daiichi Sankyo withdrew a US application for ifinatamab deruxtecan after FDA said data didn't support accelerated approval, delaying a pipeline candidate.
These events pressure Keytruda's dominance and remove a near-term pipeline catalyst, weighing on sentiment.
Measles outbreak boosts demand for Merck's MMR vaccine A US measles outbreak with 3,471 cases and 95% in unvaccinated people increases demand for Merck's MMR vaccine. This provides a modest but steady revenue lift from an existing product.
Rising disease incidence directly drives higher vaccine sales for Merck.

7 Sep – 18 Sep 2026

▲3▼1

Merck's Pipeline Push and Keytruda Defense Drive the Story

Pipeline triples to offset Keytruda patent cliff Merck's phase III pipeline has nearly tripled since 2021, with 20 new drug launches expected by 2030 to replace Keytruda's 2028 patent loss. Acquisitions like Verona, Cidara and Terns add new growth. This reassures investors that the coming revenue drop may be a shallow dip, supporting the stock.
This is the central strategic force behind Merck's valuation and directly addresses its biggest risk.
Q2 sales beat, guidance raised, Keytruda strong Merck reported Q2 sales of $16.6 billion, with Keytruda franchise at $8.4 billion, and raised full-year 2026 guidance to $66.3–$67.3 billion. Winrevair jumped 75% to $588 million. Solid results and confident outlook support the stock, though a $5.7 billion acquisition charge caused a reported loss.
Earnings and guidance are key fundamental drivers that show current business strength and future expectations.
Keytruda rival shows survival advantage Summit's ivonescimab cut death risk by 27% versus Keytruda in a lung cancer trial, with an 8.2-month survival advantage. This is a direct competitive threat to Merck's biggest drug, pressuring the stock as it raises doubts about Keytruda's long-term dominance.
This is a major competitive development that could erode Keytruda's franchise, a core part of Merck's value.
EU approval advances Keytruda bladder cancer combo EU regulators gave a positive opinion for Keytruda plus Padcev in resectable muscle-invasive bladder cancer, with final approval expected by Q4 2026. This expands Keytruda's use into earlier-stage disease, adding a new revenue stream and strengthening the franchise.
Regulatory progress opens a new market for Keytruda, directly supporting future sales growth.

30 Aug – 4 Sep 2026

▲3▼1

Merck's mRNA cancer vaccine win lifts outlook, but Keytruda rivals close in

mRNA cancer vaccine success drives healthcare rally Merck and Moderna's personalized mRNA cancer vaccine met its main Phase 3 goal in melanoma, cutting recurrence when added to Keytruda. The news sparked a broad healthcare rally, with Merck up 12% in a day and the sector posting its best week since June. This opens a major new growth path for Merck's oncology business.
This is the biggest new event of the period, directly boosting Merck's growth outlook and stock.
Analysts see multi-billion sales potential for vaccine Barclays estimates the vaccine could generate up to $3 billion in annual melanoma sales by 2035, and the global melanoma drug market is projected to grow from $5.8 billion in 2024 to $10.3 billion by 2030. This supports expectations of a meaningful new revenue stream for Merck.
It quantifies the financial upside of the vaccine, which is key to why Merck's stock is moving.
LIPFENDRA approval opens high-growth cholesterol market Merck's LIPFENDRA, the first oral PCSK9 cholesterol drug, has been approved by the FDA, driving the PCSK9 inhibitor market into a high-growth phase. This adds a new cardiometabolic pillar to Merck's business, diversifying revenue beyond Keytruda and supporting long-term growth.
It shows a new approved product expanding Merck's revenue base, which investors view positively.
Keytruda biosimilar and rival lung cancer threat Cipla's US unit secured exclusive rights to commercialize a proposed pembrolizumab biosimilar ahead of Keytruda's 2028 patent expiry. Separately, Summit Therapeutics' ivonescimab showed superior overall survival versus Keytruda in a lung cancer trial. These developments increase competition and pressure Merck's biggest franchise.
It is the main counterweight to the positive news, highlighting risks to Merck's key revenue source.

August 202627 Jul – 28 Aug 2026

▲2▼2

Merck beats Q2, raises guidance, but acquisition charges and mRNA vaccine risks temper outlook

Q2 Beat and Raised Guidance Merck reported Q2 revenue of $16.61 billion, beating estimates, and raised its full-year 2026 revenue guidance to $66.3–67.3 billion, signaling confidence in its core business.
This is a new positive development that directly supports the stock by showing better-than-expected financial performance and improved future outlook.
mRNA Cancer Vaccine Phase 3 Win Merck and Moderna's mRNA cancer vaccine succeeded in a Phase 3 melanoma trial, the first such win, with analysts projecting up to $54 billion in peak sales and testing in nine cancer trials.
This is a major new pipeline breakthrough that could drive long-term growth and is a key reason for investor optimism.
Acquisition Charges Cause Quarterly Loss Multibillion-dollar charges from acquisitions of Bio-Techne, Cidara, and Terns pushed Merck to a quarterly loss, pressuring reported earnings despite the revenue beat.
This new negative factor explains why reported earnings were weak and could weigh on investor sentiment.
mRNA Vaccine Unapproved and Biotech Volatility The mRNA cancer vaccine remains unapproved, so revenue depends on regulatory review, and Moderna's 20% post-surge plunge highlights the volatility of biotech stocks, adding uncertainty.
This new risk factor tempers the positive vaccine news and could lead to stock price swings.

8 Aug – 28 Aug 2026

▲3

Merck Hits 52-Week High on mRNA Cancer Vaccine Win and Pipeline Push

First Phase 3 win for mRNA cancer vaccine with Moderna Merck and Moderna's personalized mRNA cancer vaccine met its main goal in a Phase 3 melanoma trial, cutting recurrence when added to Keytruda. This is the first late-stage win for an mRNA cancer therapy, opening a new growth path for Merck's oncology business.
This is the biggest new catalyst driving MRK's stock to a 52-week high.
Analysts see multi-billion sales potential for the vaccine Bank of America raised its peak sales estimate for the vaccine to $54 billion and upgraded Moderna, noting Merck shares 50% of the economics. Barclays sees about $3 billion in annual melanoma sales by 2035. This supports expectations of a meaningful new revenue stream.
Analyst upgrades and sales estimates directly influence investor expectations and stock price.
Broader pipeline expansion across cancers The companies are testing the vaccine-Keytruda combo in nine Phase 2 and Phase 3 trials covering lung, bladder, kidney, pancreatic and gastric cancers. Success in more tumor types would further extend Keytruda's franchise and diversify Merck's revenue beyond its current uses.
Pipeline expansion reduces reliance on Keytruda and supports long-term growth narrative.
Moderna's sharp reversal shows volatility Moderna shares plunged 20% the day after a 177% surge, a reminder that early-stage biotech wins can be volatile. For Merck, the milestone is real but the vaccine is not approved yet, and near-term revenue depends on regulatory review and further trial results.
This counterweight reminds investors that the vaccine is not yet approved and near-term revenue is uncertain.

19 Aug – 20 Aug 2026

▲3

Merck Jumps on First mRNA Cancer Vaccine Win with Moderna

Phase 3 mRNA cancer vaccine success Merck and Moderna's personalized mRNA cancer vaccine met its main goal in a Phase 3 melanoma trial, cutting recurrence when added to Keytruda. This is the first late-stage win for an mRNA cancer therapy, opening a new growth path for Merck's oncology business.
This is the single new event that drove Merck's stock up over 11% and sets up a potential new product.
Analysts see multi-billion sales potential Bank of America raised its peak sales estimate for the vaccine to $54 billion and upgraded Moderna, noting Merck shares 50% of the economics. Barclays sees about $3 billion in annual melanoma sales by 2035. This supports expectations of a meaningful new revenue stream.
Analyst estimates quantify the financial upside for Merck, reinforcing the positive stock reaction.
Broader pipeline expansion across cancers The companies are testing the vaccine-Keytruda combo in nine Phase 2 and Phase 3 trials covering lung, bladder, kidney, pancreatic and gastric cancers. Success in more tumor types would further extend Keytruda's franchise and diversify Merck's revenue beyond its current uses.
It shows the win is not a one-off but part of a larger strategy that could drive long-term growth.
Moderna's sharp reversal shows volatility Moderna shares plunged 20% the day after a 177% surge, a reminder that early-stage biotech wins can be volatile. For Merck, the milestone is real but the vaccine is not approved yet, and near-term revenue depends on regulatory review and further trial results.
It provides a fair counterweight: the excitement is justified but not without risk, and Merck's own stock move was more measured.

27 Jul – 6 Aug 2026

▲3

Merck Beats Q2, Raises Guidance as Keytruda and New Drugs Expand

Q2 Beat and Raised 2026 Guidance Merck reported Q2 revenue of $16.61 billion, up 5% and above estimates, with Keytruda sales of $8.37 billion. Management raised full-year 2026 revenue guidance to $66.3–$67.3 billion. This directly boosts investor confidence and supports a higher stock price.
This is the period's biggest new financial catalyst, showing stronger-than-expected results and a brighter outlook.
Keytruda Label Expansions in Canada and EU Diagnostic Health Canada approved Keytruda with enfortumab vedotin for bladder cancer, and Agilent's EU companion diagnostic helps identify more patients for Keytruda. These expand Keytruda's use into new patient groups, supporting future sales growth as Merck faces eventual patent expiration.
New approvals and diagnostic tools widen Keytruda's market, a key growth driver for Merck.
New Drug Approvals and Pipeline Progress FDA approved LIPFENDRA, the first oral PCSK9 cholesterol drug, adding a new cardiometabolic pillar. Merck also advanced HIV prevention access and reported positive Phase 3 results for a once-weekly HIV regimen. These diversify revenue beyond Keytruda and support long-term growth.
These new products and pipeline wins show Merck building future revenue streams, reducing reliance on Keytruda.
Acquisition Charges Weigh on Reported Earnings Merck's $11.3 billion Bio-Techne and $9 billion Cidara acquisitions, plus a $5.7 billion Terns charge, caused a reported quarterly loss. While these deals aim to replenish the pipeline, the large cash outlays and charges pressure near-term reported profits and could weigh on sentiment.
This is the main counterweight: big spending and accounting losses offset strong operational results.

July 202630 Jun – 24 Jul 2026

▲2▼2

Merck's Pipeline Wins Offset Generic and Regulatory Pressures

Keytruda Label Expansion and Phase 3 Win Keytruda won U.S. and EU approvals in breast and bladder cancer and succeeded in a Phase 3 endometrial cancer trial, expanding its use and supporting future sales.
This is a major new positive driver for Merck's top-selling drug.
New Drug Approvals and HIV Advancements The FDA approved LIPFENDRA, the first oral PCSK9 inhibitor, and Merck advanced HIV efforts with Gilead and an access plan, broadening its treatment portfolio.
These are new pipeline and label wins that could drive future revenue.
Congressional Probe into China Trials A U.S. House committee is investigating Merck's China clinical trials, raising concerns about ethics, data security, and intellectual property that could harm its reputation and operations.
This is a new regulatory and geopolitical risk that could weigh on the stock.
Generic Competition and COVID Revenue Loss Par Health launched a generic version of Janumet XR, eroding about $270 million in annual U.S. sales, while COVID-19 EUA termination removed Lagrevio revenue, pressuring overall sales.
These are new negative developments that directly reduce Merck's revenue.

15 Jul – 24 Jul 2026

▲3▼1

Merck's Pipeline Wins Outweigh Generic Erosion

Keytruda Endometrial Cancer Win Merck's Keytruda met its main goal in a Phase 3 endometrial cancer trial, showing better progression-free survival than chemotherapy. This expands Keytruda's use into a new cancer type, supporting future sales as the company faces patent expiration.
New clinical win expands Keytruda's label and supports long-term revenue.
FDA Approves First Oral PCSK9 Inhibitor LIPFENDRA Merck won FDA approval for LIPFENDRA, the first once-daily oral PCSK9 inhibitor for high cholesterol. It cut LDL-C by up to 59% in trials and offers an easier option than injectables, opening a large new market for Merck.
New product approval opens a major new revenue stream beyond oncology.
HIV Pipeline Advances with Gilead and Access Plan Merck and Gilead reported positive Phase 3 results for a once-weekly oral HIV regimen, and Merck unveiled an early access plan for its once-monthly HIV prevention pill in 129 low- and middle-income countries. These moves strengthen Merck's HIV franchise and future demand.
New HIV data and access strategy expand Merck's pipeline and global reach.
Generic Janumet XR Launch Erodes Sales Par Health launched the first generic version of Merck's Janumet XR diabetes drug in the U.S. This will cut into Merck's sales of the branded product, which had about $270 million in annual U.S. revenue, as cheaper copies take market share.
New generic competition directly pressures an existing Merck product's revenue.

30 Jun – 10 Jul 2026

▲2▼2

Merck's Keytruda Label Wins Offset China Probe and COVID Drug Loss

U.S. House Committee Probes Merck's China Clinical Trials A House committee is investigating Merck's clinical trials at Chinese military sites and in Xinjiang, raising concerns about ethics, data security, and intellectual property. This regulatory and headline risk could weigh on the stock, especially if it leads to restrictions or reputational damage.
This is a new negative regulatory event that introduces uncertainty and potential downside for MRK.
COVID-19 EUA Termination Hits Merck's Lagrevio The U.S. government ended emergency use authorizations for COVID-19 drugs, including Merck's Lagrevio. This removes a revenue stream and could lower future sales expectations, though the impact may be limited if COVID-19 remains endemic and traditional approvals are pursued.
This is a new regulatory change that directly reduces Merck's COVID-19 product sales.
Keytruda Wins New U.S. and EU Approvals in Breast and Bladder Cancer Merck received FDA and EU approvals for Keytruda-based regimens in triple-negative breast cancer and muscle-invasive bladder cancer, including a subcutaneous form. These expand Keytruda's label into earlier and tougher tumors, supporting sales growth as the company prepares for patent expiration.
These new approvals broaden Keytruda's market and reinforce Merck's oncology strategy, a key positive driver.
Tulisokibart Phase 3 Success Strengthens Immunology Pipeline Merck's anti-TL1A antibody tulisokibart met its main goal in a Phase 3 ulcerative colitis trial. This is a first for this drug class and helps diversify Merck beyond oncology, offsetting future Keytruda competition and supporting long-term growth.
This pipeline win is a new positive development that boosts Merck's diversification efforts.

Q2 202617 Jun – 26 Jun 2026

▲3▼1

Merck's Pipeline and Label Wins Offset Medicare Pricing Threat

Tulisokibart Phase 3 Win Boosts Immunology Pipeline Merck's anti-TL1A antibody tulisokibart met the main goal in a Phase 3 ulcerative colitis trial, a first for this type of drug. This strengthens Merck's pipeline beyond cancer and helps offset future Keytruda competition, supporting the stock.
This is a new positive pipeline event that directly addresses Merck's post-Keytruda growth story.
FDA and EU Approvals Expand Keytruda, Welireg, and Capvaxive Labels Merck won new approvals for Keytruda+Welireg in kidney cancer, Capvaxive in children, and Keytruda+Padcev in bladder cancer in the EU. These expand patient populations and should lift sales of these drugs.
These are new regulatory wins that broaden Merck's marketed products and drive revenue growth.
Proposed CMS Rule to Make Medicare Drug Price Negotiations Permanent A proposed CMS rule would make Medicare drug price negotiations permanent, directly pressuring Merck's pricing. This regulatory overhang could cap future revenue growth and weighs on the stock.
This is a new regulatory threat that could negatively impact Merck's pricing and profits.
Abu Dhabi Logistics Hub to Expand Regional Distribution Merck (MSD) is partnering with Abu Dhabi to explore a regional logistics hub, which could improve supply chain resilience and access to its therapies in the Middle East. This supports long-term demand.
This new partnership could enhance Merck's distribution and market access in a growing region.

June 202617 Jun – 26 Jun 2026

▲3▼1

Merck's Pipeline and Label Wins Offset Medicare Pricing Threat

Tulisokibart Phase 3 Win Boosts Immunology Pipeline Merck's anti-TL1A antibody tulisokibart met the main goal in a Phase 3 ulcerative colitis trial, a first for this type of drug. This strengthens Merck's pipeline beyond cancer and helps offset future Keytruda competition, supporting the stock.
This is a new positive pipeline event that directly addresses Merck's post-Keytruda growth story.
FDA and EU Approvals Expand Keytruda, Welireg, and Capvaxive Labels Merck won new approvals for Keytruda+Welireg in kidney cancer, Capvaxive in children, and Keytruda+Padcev in bladder cancer in the EU. These expand patient populations and should lift sales of these drugs.
These are new regulatory wins that broaden Merck's marketed products and drive revenue growth.
Proposed CMS Rule to Make Medicare Drug Price Negotiations Permanent A proposed CMS rule would make Medicare drug price negotiations permanent, directly pressuring Merck's pricing. This regulatory overhang could cap future revenue growth and weighs on the stock.
This is a new regulatory threat that could negatively impact Merck's pricing and profits.
Abu Dhabi Logistics Hub to Expand Regional Distribution Merck (MSD) is partnering with Abu Dhabi to explore a regional logistics hub, which could improve supply chain resilience and access to its therapies in the Middle East. This supports long-term demand.
This new partnership could enhance Merck's distribution and market access in a growing region.

17 Jun – 26 Jun 2026

▲3▼1

Merck's Pipeline and Label Wins Offset Medicare Pricing Threat

Tulisokibart Phase 3 Win Boosts Immunology Pipeline Merck's anti-TL1A antibody tulisokibart met the main goal in a Phase 3 ulcerative colitis trial, a first for this type of drug. This strengthens Merck's pipeline beyond cancer and helps offset future Keytruda competition, supporting the stock.
This is a new positive pipeline event that directly addresses Merck's post-Keytruda growth story.
FDA and EU Approvals Expand Keytruda, Welireg, and Capvaxive Labels Merck won new approvals for Keytruda+Welireg in kidney cancer, Capvaxive in children, and Keytruda+Padcev in bladder cancer in the EU. These expand patient populations and should lift sales of these drugs.
These are new regulatory wins that broaden Merck's marketed products and drive revenue growth.
Proposed CMS Rule to Make Medicare Drug Price Negotiations Permanent A proposed CMS rule would make Medicare drug price negotiations permanent, directly pressuring Merck's pricing. This regulatory overhang could cap future revenue growth and weighs on the stock.
This is a new regulatory threat that could negatively impact Merck's pricing and profits.
Abu Dhabi Logistics Hub to Expand Regional Distribution Merck (MSD) is partnering with Abu Dhabi to explore a regional logistics hub, which could improve supply chain resilience and access to its therapies in the Middle East. This supports long-term demand.
This new partnership could enhance Merck's distribution and market access in a growing region.